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Incidence and factors associated with
geographical relocation in patients
receiving renal replacement therapy
Hicham I Cheikh Hassan1,2* , Jenny HC Chen1,2,3 and Karumathil Murali1
Abstract
Background: Renal replacement therapy (RRT) places a burden on patients, and geographical relocation for easier
access to healthcare facilities is a necessity for some. Incidence and factors associated with relocation has not been
comprehensively examined at a national level. We aimed to determine proportion, incidence, characteristics of RRT
patients who relocate and relocation rate by remoteness of residence and dialysis modality.
Methods: Retrospective cohort analysis using Australian and New Zealand Dialysis and Transplant Registry to
examine RRT patients in Australia from January 2005 to December 2015. Relocation incidence was calculated for
remoteness of residence and RRT modality as rate per 100 patient years. Factors associated with relocation were
examined using competing risk regression models with death as a competing event.
Results: Of 24,676 incident patients on RRT, 5888 (23.9%) relocated with a median time of 1.6 years [IQR 0.7–3.4]
years. Relocation incidence was 7.9 per 100 patient years and increased from major cities to very remote regions
(7.2 to 48.8 per 100 patient years respectively, p < 0.001). Remoteness of residence was associated with
geographical relocation in competing risk analysis especially in remote (SHR 1.20, 95%CI 1.01, 1.41 p = 0.034) and
very remote regions (SHR 3.51 95% 3.05, 4.04 p < 0.001). Aboriginal or Torres Strait Islander ethnicity, compared to
Caucasian, was independently associated with relocation (SHR 1.18, 95% CI 1.06,1.31, p = 0.002) while transplant
patients were less likely to relocate compared to haemodialysis patients (HR 0.37, 95%CI 0.34, 0.39, p < 0.001).
Conclusions: Relocation in patients receiving RRT is associated with remoteness of residence, RRT modality and
ethnicity. Reasons for relocation and its impact on patient wellbeing and outcome should be further explored.
Keywords: End stage kidney disease, Renal replacement therapy, Geographic relocation, Patient impact, Healthcare
access
Background
Globally, the number of people requiring renal replace-
ment therapy (RRT) is rising [1]. RRT places a high bur-
den on health resources in the form of regular clinic
appointments, investigations, interventions and routine
dialysis attendance in specialised centres. Given the
complexity of RRT treatment many patients find them-
selves facing factors necessitating a need to geographic-
ally relocate.
Relocation in patients receiving RRT has not been stud-
ied extensively. Observational studies have shown that in-
creased travel time to a treatment center for
haemodialysis (HD) is associated with lower HD preva-
lence, poorer quality of life and higher all-cause mortality
[2–6]. Another factor associated with relocation is access
to treatment by remoteness of residence. In Australia,
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rural and regional residents with chronic diseases had
fewer physician visits, more difficulty accessing health ser-
vices and a higher mortality compared to their urban
counterparts [7–10]. RRT patients who lived in regional
districts, compared to patients in urban centers, used a
lower proportion of dialysis care and had worse survival
[4, 5, 11, 12]. Both the travel time and access to healthcare
are potential reasons for the lower prevalence of dialysis
in rural Australia compared to major cities [4, 12].
While relocation offers health benefits and easier
access to health services, it also causes significant stress
on the patient and family. Patients who relocated from
rural areas for better health care access often face separ-
ation from family, lack of social support and financial
burdens [13, 14]. Dialysis patients who relocated de-
scribed a decline in willingness to maintain treatment
regimens [15]. The final decision to relocate is likely to
involve a trade-off between benefits of being closer to
family, friends and a familiar social environment (favour-
ing non-relocation) and health benefits of being closer
to a treatment centre in a major health centre (favouring
relocation).
The aims of our study were three-fold. Firstly, we ex-
amined characteristics of patients with end-stage kidney
disease who relocated and who did not relocate after
commencement of RRT. Secondly, we assessed the inci-
dence and pattern of relocation between metropolitan,
rural and remote areas. Lastly, we determined the associ-
ation between geographical remoteness and RRT modal-
ity with relocation rates.
Methods
Study design and setting
We conducted a retrospective cohort study using the
Australia and New Zealand Dialysis and Transplant
Registry (ANZDATA). ANZDATA collects yearly infor-
mation (ending December 31) on all receiving RRT in
Australia and New Zealand. Notification of RRT modal-
ity change, treatment centre change and death occurs in
real time. Permission to analyse the data was granted by
the ANZDATA executive. Only de-identified data were
analysed, and the need for informed consent was waived.
Participants
Adult (≥18 years) patients who initiated RRT in Australia
between January 12,005 and December 31,2015, were
alive or remained on RRT for > 6 months and who did
not recover renal function were included in the study.
The year 2005 was chosen since postcode information
was recorded from 2005 onwards on a yearly basis at the
end of the calendar year. We excluded New Zealand pa-
tients (due to incomplete postcode information), patients
with no postcode history, those with > 6 months between
start date and postcode documentation date and patients
who relocated to or from an overseas location.
Data collection
Baseline patient characteristics were collected at the ini-
tiation of RRT and included age, gender, ethnicity, co-
morbidity and cause of renal disease. Comorbidities
recorded include: diabetes, peripheral vascular disease,
chronic lung disease, coronary artery disease and cere-
brovascular disease. Ethnicity was classified as Cauca-
sian, Asian, Aboriginal and Torres Strait Islander
(ATSI), Maori-Pacific Islander (MPI) and Other. Causes
of renal disease were classified as glomerulonephritis,
diabetes, hypertension, cystic disease and other.
RRT modality was categorised as transplant, home
therapies and facility HD at the start of initiating RRT
and at the end of the study period (first relocation or
censoring). We combined peritoneal dialysis and home
HD since both belong to the same the category of
home-based therapies and have similar implications for
relocation. If treatment centre or state changed in the
year of relocation, then the RRT modality at the time of
change was chosen. If RRT modality changed during the
year of relocation, then the newer RRT modality was
chosen if RRT modality changed in the first 6 months of
the year and the older RRT modality if the change oc-
curred in the second 6months of the year. For patients
who did not relocate we assigned the RRT modality at
censoring.
Remoteness of residence was determined from the
postcode using the Accessibility/ Remoteness Index of
Australia taken from the Australia Bureau of Statistics
using Australian Standard Geographical Classification
from the 2011 census data [16]. There are five classes of
major city, inner regional, outer regional, remote and
very remote based on physical road distance from a loca-
tion to the nearest urban centre. We also further exam-
ined relocations from and to major city by change of
state, which would indicate that a relocation occurred to
a new city compared to within the same city.
Exposure factor
Geographical relocation was defined as the first change
in postcode. Postcode was captured by ANZDATA at
the end of the calendar year (December 31st) while
treatment centre or state change occurred in real time.
Relocation date was set as end of the calendar year. If a
treatment centre, state change or death occurred in the
same year as a geographical relocation, then the exact
date was used as the relocation date. Patients were cen-
sored on death, loss of follow-up or on reaching end of
study period.
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Statistical analysis
Categorical data were expressed as number (percent-
age) and analysed using chi-square. Continuous data
were was expressed as mean (standard deviation) or
median (interquartile range) and analysed as per dis-
tribution. Incidence was calculated as the number of
relocations divided by total patient years. We calcu-
lated the incidence for the total cohort, by remote-
ness of residence and by RRT modality as rate per
100 patient-years. Incidence of net patient gain or
loss due to relocation for each remoteness of resi-
dence category was calculated from the difference be-
tween the total number of patients relocating to and
leaving the remoteness of residence and dividing by
the total patient years for the remoteness of resi-
dence. Factors associated with relocation were exam-
ined by fitting Cox proportional hazards models and
competing risk analysis. A multivariable Cox propor-
tional hazards model for time from RRT commence-
ment to the first relocation was constructed using a
backward selection procedure. Covariates with p-value
≤0.2 in the univariate analyses were included in the
model. Interaction between remoteness of residence
and ethnicity was tested using Wald test and found
not to be significant (p = 0.7). Proportional hazards
assumptions were confirmed graphically by plotting
the Schoenfeld’s residuals. We also used Fine-Gray’s
extension of the Cox proportional hazards model to
fit competing risk regression models using death as a
competing event. The covariates for Cox proportional
hazards models and competing risk analysis were the
same. Remoteness of residence and ethnicity were in-
cluded in all models for their previously established
associations. Results were expressed as hazard ratio
(HR) and sub-hazard ratio (SHR) with 95% confidence
interval (95%CI). We used listwise deletion to handle
missing data. Statistical analysis was preformed using
Stata (version 14.0).
Results
Of the 30,188 adult patients who commenced RRT from
2005 to 2015, the following patients were excluded: 5160
from New Zealand, 87 with no postcode history, 19 who
had no postcode history for > 6 months and 246 who
relocated from or to overseas. In total 24,676 incident
patients commenced RRT in Australia between 2005
and 2015, 5888 (23.9%) patients relocated and 18,788
(76.1%) did not. The patients were followed-up for a me-
dian [IQR] time of 2.2 [0.8,4.5] years with total follow-
up time of 74,039.7 patient years. The study population
was predominantly Caucasian (74.1%) with mean (SD)
age of 60.3 (15.4) years and a high prevalence of comor-
bidities (65.8%) (Table 1). Most started RRT on facility
HD (70.4%) and lived in a major city (66.6%).
Geographical relocation
Patients who relocated were more likely, when compared to
those who did not relocate, to be younger (55.4 vs 61.8 years,
p < 0.001), of ATSI background (19.3% vs 8.3%, p < 0.001)
and be from a remote (3.7% vs 2.2%, p < 0.001) or very re-
mote area (9.7% vs 1.5%, p < 0.001) (Table 1). The median
time to relocation was 1.6 [IQR, 0.7–3.4] years (Table 2).
Time from RRT commencement to relocation is shorter in
patients from an ATSI background (p < 0.001), with a comor-
bidity (1.5 vs 2.1 years, p < 0.001) and who received facility
HD compared to home therapies and transplant (1.4 vs 1.5 vs
3.9 years, respectively, p < 0.001). Time to relocation is also
shorter as remoteness of residence changed from major city
to very remote areas (2.0 vs 0.6 years, p for trend < 0.001).
Incidence and pattern of geographical relocation
Incidence of relocation in the total RRT cohort was 7.9
per 100 patient years (95% CI 7.4–8.5). Incidence in-
creased across remoteness of residence within each geo-
graphical area reaching in major city 7.2 per 100 patient
years (95% CI 6.6–7.8), in inner regional areas 5.9 per
100 patient years (95% CI 4.8–7.1), in outer regional
areas 8.6 per 100 patient years (95% CI 6.9–10.3), in re-
mote areas 13.5 per 100 patient years (95% CI 9.8–17.2)
and in very remote areas 48.8 per 100 patient years (95%
CI 45.6–51.9) (p < 0.001). Most relocations (4083, 70.6%)
occurred within same remoteness of residence (Table 3)
with more than half the relocations (56.5%) occurring
within major cities (incidence 4.4 per 100 patient years).
For within major city relocation only 7.4% were accom-
panied with a change of state indicating that more than
90% of major city to major city relocations occurred in
the same city.
Relocation rate by RRT modality increased from 5.4
per 100 patient years (95% CI 4.9–5.7) for transplant, 7.3
per 100 patient years (95%CI 6.9–7.7) for home therap-
ies to 9.4 per 100 patient (95% CI 9.1–9.7) years for fa-
cility HD (p < 0.001).
For all RRT patients the net relocation by remoteness of
residence was a gain of 0.12 per 100 patient years for
major cities, 0.12 per 100 patient years for inner regional,
0.24 per 100 patient years for outer regional and 0.13 per
100 patient years for remote. There was a net loss of 0.65
per 100 patient years for very remote regions.
Factors associated with geographical relocation
Variables associated with relocation was determined
using Cox proportional hazard models (Table 4). A
strong association was found for ethnicity, RRT at re-
location and remoteness of residence. This remained the
case in the competing risk analysis with transplant asso-
ciated with a lower risk compared to facility HD as the
RRT modality (SHR 0.37, 95%CI 0.34–0.40, p < 0.001)
(Fig. 1). Ethnicity and remoteness of residence remained
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an independent risk for relocation with ATSI having a
SHR of 1.18 (95%CI 1.06–1.31, p = 0.002), being from a
remote region SHR 1.20 (95%CI 1.01–1.42, p = 0.034)
and very remote region SHR 3.51 (95%CI 3.05–4.04, p <
0.001).
Discussion
This is the first study to our knowledge describing geo-
graphical relocation in RRT patients, or any patient
group with chronic diseases, on a national level. We
found 23.9% of Australian RRT patients between 2005
Table 1 Baseline characteristics of study cohort with comparison between the relocation and non-relocation group
All patients (n = 24,676) Relocation (n = 5888,23.9%) Non-relocation (n = 18,788, 76.1%)
Gender (Male) 15,172 (61.5%) 3498 (59.4%) 11,674 (62.1%)
Age (years) 60.3 (15.4) 55.4 (16.2) 61.8 (14.8)
Race
Caucasian 18,142 (74.1%) 3876 (66.0%) 14,266 (76.6%)
Asian 2274 (9.3%) 517 (8.8%) 1757 (9.4%)
ATSI 2669 (10.9%) 1131 (19.3%) 1538 (8.3%)
MPI 765 (3.1%) 226 (3.8%) 539 (2.9%)
Other 635 (2.6%) 121 (2.1%) 514 (2.8%)
Comorbidities
Any 16,228 (65.8%) 3781 (64.2%) 12,447 (66.2%)
Diabetes 11,570 (47.0%) 2853 (48.5%) 8717 (46.5%)
CLD 3021 (12.7%) 641 (11.3%) 2380 (13.1%)
CAD 8077 (34.7%) 1765 (31.6%) 6312 (35.7%)
PVD 4306 (18.6%) 993 (17.9%) 3313 (18.8%)
CerebVD 2775 (11.6%) 610 (10.6%) 5156 (11.9%)
Cause of Primary Renal Disease
Glomerulonephritis 5494 (22.4%) 1446 (24.6%) 4048 (21.7%)
Diabetes 8803 (35.9%) 2265 (38.5%) 6538 (35.0%)
Hypertension 3262 (13.3%) 663 (11.3%) 2599 (13.9%)
Cystic disease 1751 (7.1%) 392 (6.7%) 1359 (7.3%)
Other 5242 (21.4%) 1117 (19.0%) 4125 (22.1%)
First RRT modality
Facility HD 17,363 (70.4%) 5888 (73.8%) 13,015 (69.3%)
Home Therapies 6430 (26.1%) 1331 (22.6%) 5099 (27.1%)
Transplant 883 (3.6%) 209 (3.5%) 674 (3.6%)
RRT modality at relocation or censoring
Facility HD 14,331 (58.1%) 3617 (61.4%) 10,714 (57.0%)
Home Therapies 5750 (23.3%) 1433 (24.3%) 4317 (23.0%)
Transplant 4595 (18.6%) 838 (14.2%) 3757 (20.0%)
Urbanity
Major 16,433 (66.6%) 3652 (62.6%) 12,781 (68.1%)
Inner Regional 4301 (17.5%) 805 (13.8%) 3496 (18.6%)
Outer Regional 2397 (9.7%) 599 (10.3%) 1798 (9.6%)
Remote 635 (2.6%) 214 (3.7%) 421 (2.2%)
Very Remote 843 (3.4%) 567 (9.7%) 276 (1.5%)
Data expressed as numbers (percentage) or mean (standard deviation)
All variables statistically significant (P < 0.05) except for PVD
Number (%) of missing data: 191 (0.8%) in race, 55 (0.2%) in diabetes status, 875 (3.5%) in chronic lung disease, 1397 (5.7%) in coronary artery disease, 1533
(6.2%) in peripheral vascular disease, 685 (2.8%) in cerebral vascular disease and 124 (0.5%) in cause of primary renal disease,
RRT Renal replacement therapy, HD Hemodialysis, ATSI Australia and Torres Strait Islander, MPI Maori Pacific Islander, CLD Chronic Lung Disease, CAD Coronary
artery disease, PVD Peripheral vascular disease, CerebVD Cerebrovascular disease
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and 2015 relocated, with a relocation incidence of 7.9
per 100 patient years. The proportion is higher than pre-
vious estimates of 5%, found in New South Wales in
Australia [17], and 15%, calculated from the difference
in age adjusted dialysis prevalence for urban vs rural
areas in a Japanese prefecture [4]. The increased propor-
tion in our analysis likely resulted from including
relocation within same remoteness of residence index
and examining a national registry over a 10-year period.
We highlighted the high relocation rate with increas-
ing remoteness of residence index, with patients relocat-
ing more frequently and earlier from outer regional,
remote and very remote regions towards the major city
and inner regional areas. There are likely two main fac-
tors encouraging patients on RRT to geographically re-
locate; distance to a treatment centre and rurality.
Distance to a treatment centre with corresponding travel
time may add hours to an already lengthy treatment ses-
sion. The higher incidence of relocation found in facility
HD compared to transplant is evidence of the burden
frequent travel for treatment could impose.
There is a clear decrease in prevalence of facility HD
with increased distance and travel time from a treatment
centre [3–6]. Prevalence is estimated to decrease by 5.5%
for every 10 min increase in travel time between resi-
dence and treatment centre [4] with prevalence signifi-
cantly decreasing once travel time exceeds 15min [5, 6].
An increase in the distance between patient residence
and treatment centre is also associated with an increase
in all-cause mortality [2, 18] and mortality from infec-
tion [18]. It was previously hypothesized that the de-
crease in prevalence with increasing travel time is a
result of increased mortality or withdrawals [2, 19], how-
ever our analysis supports the notion that patient reloca-
tion is also an important factor.
The second factor encouraging geographical relocation
is rurality. Australian rural patients with chronic diseases
undergo fewer diagnostic or therapeutic interventions
compared to urban centres, [10, 19–23] highlighting an
inequality in the provision of health services. This ex-
tends to rural RRT patients who have a lower health ser-
vice utilisation, physician visits and proportion of
dialysis care [4, 5, 12, 17]. Australian RRT patients in re-
gional districts, compared to major cities, have a lower
survival and higher risk of hospitalisation [12, 17] while
transplant patients in major cities are less likely to have
an acute rejection in the first 6 months post-transplant
[12]. While we found the absolute number of relocations
from rural areas to be low when compared to urban cen-
tres it does highlight the greater burden which RRT pa-
tients experience in these regions.
We found the risk of relocation among indigenous
population significant. Indigenous populations on RRT
remain susceptible to relocation given rural urbanity in
Canada [13] and Australia where relocation rates can
reach 50% in some communities [24]. The burden of ill-
ness suffered by native populations is further compli-
cated by the difficulty in providing specialised tertiary
level care to geographically isolated small communities.
Geographic relocation for better access to specialised
treatment facilities does come with costs in the form of
Table 2 Time from commencement of renal replacement to
relocation in relocation cohort
Time to relocation (years)
Relocation Group 1.6 [0.7, 3.4]
Gender
Male 1.7 [0.7, 3.4]
Female 1.6 [0.7, 3.3]
Race
Caucasian 1.9 [0.8, 3.6]
Asian 1.9 [0.9, 3.8]
ATSI 0.9 [0.4, 2.0]
MPI 1.7 [0.8, 2.9]
Other 1.8 [0.7, 3.2]
Comorbidity
Yes 1.5 [0.7, 3.0]
No 2.1 [0.9, 4.0]
Cause of Primary Renal Disease
Glomerulonephritis 1.9 [0.8, 3.8]
Diabetes 1.4 [0.6, 2.9]
Hypertension 1.7 [0.7, 3.3]
Cystic disease 2.4 [1.0, 4.2]
Other 1.7 [0.8, 3.4]
RRT at relocation
Facility HD 1.4 [0.6, 3.0]
Home Therapies 1.5 [0.7, 2.6]
Transplant 3.9 [2.3, 5.6]
Urbanity (from)
Major City 2.0 [0.9, 3.8]
Inner Regional 1.8 [0.8, 3.3]
Outer Regional 1.4 [0.7, 2.9]
Remote 1.3 [0.5, 2.5]
Very remote 0.6 [0.3, 1.2]
Urbanity (to)
Major City 1.9 [0.8, 3.6]
Inner Regional 1.8 [0.8, 3.5]
Outer Regional 1.1 [0.4, 2.4]
Remote 0.8 [0.4, 1.6]
Very remote 1.3 [0.7, 2.6]
Data expressed as median [intraquartile range]. Analysis by Log rank test for
study cohort
All variables statistically significant (P < 0.05)
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significant financial, cultural and psychological pressure
on the patient [15]. Patients may face family separation
and a lack of social support [13, 14] with significant det-
rimental effects on quality of life and ability and willing-
ness to maintain treatment regimens [15]. Some patients
struggle with the idea of relocating by themselves and
are faced with the burden of relocating the whole family
[14]. A better understanding of the reasons behind re-
location (personal or as a necessity for easier access to
treatment), factors influencing this decision and the im-
pact it causes is needed. Such information would also in-
form health policy makers to enable optimization of
Table 3 Geographical relocation breakdown by direction of urbanity
Relocation to
Relocation from Major City Inner Regional Outer Regional Remote and Very Remote Total
Major City 3268 (89.9%) 267 (7.3%) 73 (2.0%) 26 (0.7%) 3634 (62.8%)
Inner Regional 255 (31.9%) 464 (58.0%) 69 (8.6%) 12 (1.5%) 800 (13.8%)
Outer Regional 129 (21.9%) 125 (21.2%) 306 (51.9%) 27 (4.6%) 590 (10.2)
Remote and Very Remote 121 (15.9.0%) 32 (4.2%) 314 (41.3%) 83 (10.9%) 759 (13.1%)
Total 3773 (65.2%) 888 (15.4%) 762 (13.2%) 296 (5.1%) 5783
Table 4 Cox proportional hazard models and competing risk analysis, with death considered as a competing risk, examining risk
factors for relocation
Cox proportional hazards model
Univariate analysis
HR (95%CI)
P-value Cox proportional hazards model
Multivariate analysis
aHR (95%CI)
P-value Competing risk analysis
Multivariate analysis
SHR (95% CI)
P-value
Gender (M) 1.09 (1.03, 1.15) 0.001 – – – –
Age (per decade) 0.87 (0.85, 0.88) < 0.001 0.80 (0.78, 0.81) 0.75 (0.74, 0.77) < 0.001
Race
Caucasian Reference – Reference – Reference –
Asian 1.07 (0.97, 1.17) 0.14 0.98 (0.89, 1.08) 0.73 1.06 (0.96, 1.16) 0.27
ATSI 2.99 (2.80, 3.20) < 0.001 1.21 (1.09, 1.34) 0.001 1.18 (1.06, 1.31) 0.002
MPI 1.60 (1.40, 1.83) < 0.001 1.07 (0.97, 1.27) 0.19 1.14 (0.99, 1.31) 0.052
Other 1.46 (1.22, 1.75) < 0.001 1.25 (1.04, 1.50) 0.01 1.27 (1.07, 1.51) 0.006
Comorbidity (Yes) 1.18 (1.12,1.24) < 0.001 – – – –
Cause of Primary Renal Disease
Glomerulonephritis Reference < 0.001 – – – –
Diabetes 1.27 (1.19, 1.37) 0.4 – – – –
Hypertension 0.97 (0.88, 1.06) < 0.001 – – – –
Cystic disease 0.78 (0.70, 0.88) 0.1 – – – –
Other 0.94 (0.87, 1.02) – – – – –
RRT at relocation
Facility HD Reference – Reference – Reference –
Home Therapies 1.08 (1.02, 1.15) 0. 01 1.02 (0.96, 1.09) 0.54 0.97 (0.91, 1.04) 0.40
Transplant 0.37 (0.34, 0.39) < 0.001 0.29 (0.27, 0.32) < 0.001 0.37 (0.34, 0.40) < 0.001
Urbanity (from)
Major City Reference – Reference – Reference –
Inner Regional 0.83 (0.77, 0.89) < 0.001 0.83 (0.77, 0.90) < 0.001 0.82 (0.76, 0.89) < 0.001
Outer Regional 1.19 (1.01, 1.30) < 0.001 1.03 (0.93, 1.13) 0.59 0.99 (0.91, 1.09) 0.98
Remote 1.86 (1.62, 2.13) < 0.001 1.18 (1.01, 1.38) 0.04 1.20 (1.01, 1.42) 0.034
Very remote 6.46 (6.46, 7.06) < 0.001 3.61 (3.20, 4.10) < 0.001 3.51 (3.05, 4.04) < 0.001
HR Hazard ration, aHR adjusted hazard ratio, SHR: subdistribution hazard ratio
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health resource allocation and development of efficient
treatment networks. This is particularly true in the
Australia where provision of coordinated comprehensive
care for RRT patients can be a challenge in the setting
of a large landmass and low population density with a
sizable rural population.
Our study has several limitations. The data entered in
the ANZDATA registry is submitted by each treatment
centre, and the registry does not verify the accuracy of
these reports or missing information. The dependency
on postcode change to define a relocation likely underes-
timated the magnitude of our results. Since ANZDATA
registry identified relocations at the end of the calendar
year, the actual time to relocation is likely shorter. Our
study was an observational analysis hence we could not
prove direction of causality. We were also unable to
include patients who relocated prior to commencing
RRT or patients who were managed conservatively for
ESRD. Finally, besides distance to treating centre, other
psychosocial factors may influence the decision for re-
location including patient and family supports, housing
instability, financial security, and need for home care
which we were unable to explore. Future studies are re-
quired to explore these factors.
Conclusion
We determined the relocation incidence and prevalence
in RRT in Australia. We also established factors associ-
ated with higher relocation rates. Further studies could
be undertaken to determine the cause for relocation and
the effect relocation imposes on quality of life and
mortality.
Fig. 1 Cumulative incidence graph showing time to relocation by (a) renal replacement therapy modality and (b) remoteness of residence index, using
mortality as a competing risk to calculate cumulative incidence function estimate. (Solid line for major city and dotted line for inner regional overlapping)
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